Moderna’s CMV Vaccine Extension Study Reaches Completion, Setting the Stage for Next Growth Catalyst

Moderna (MRNA) announced an update on their ongoing clinical study.

Moderna’s latest clinical update centers on a long‑term extension of its cytomegalovirus (CMV) vaccine program, officially titled “A Phase 2, Non-Randomized, Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus mRNA-1647 Vaccine Including a Booster Dose in a Subset of Participants Who Completed Study mRNA-1647-P202.” The study tracks how well immune protection lasts over time and how safe the vaccine remains, with or without a booster dose, in adults who finished an earlier phase 2 trial. This work matters because CMV is a common infection linked to serious complications in newborns, and a successful vaccine could open a new, sizable market for Moderna.

The trial tests mRNA-1647, an mRNA-based CMV vaccine candidate designed to prevent CMV infection. It is aimed at both CMV-negative and CMV-positive adults to measure how the immune system responds over the long term. In the booster part of the study, some participants receive a single extra dose to see whether a top-up shot can maintain or raise protection and how well it is tolerated.

This is an interventional phase 2 study using a non-randomized, sequential design. Everyone in the extension phase is followed regularly over several years, rather than being randomly assigned to different doses or products. There is no blinding: both investigators and participants know who receives a booster and who does not. The main goal is preventive—assessing if the vaccine can support lasting protection and remain safe, to guide design and expectations for later-stage trials.

The study first appeared in the registry on 9 July 2021, marking the formal start of the extension effort. The trial is now listed as completed, meaning participant follow-up and data collection are finished, though full results are not yet posted. The most recent update to the record was submitted on 30 January 2026, signaling that Moderna has refreshed key administrative or status details as it prepares or reviews results. These dates matter for investors because they define when headline data and next development steps are likely to emerge.

For markets, a completed long‑term extension with a fresh 2026 update is a constructive signal for Moderna (MRNA). It suggests the CMV program is progressing on schedule and that the company is confident enough to keep investing in follow-up and booster data. Strong durability and safety results could support a large, first-in-class vaccine opportunity in congenital CMV and an important new revenue stream beyond COVID-19, which could improve sentiment around Moderna’s long-term pipeline value. Competitors in vaccines and infectious disease, such as GSK and Pfizer, may face a new entrant in a largely untapped indication, and any positive read‑through may lift broader interest in mRNA platforms. Until detailed results are released, however, share-price reaction is likely to remain modest and tied to expectations rather than confirmed outcomes.

This CMV vaccine study has been completed and recently updated, with more information available on the ClinicalTrials portal for investors tracking Moderna’s progress.

To learn more about MRNA’s potential, visit the Moderna drug pipeline page.